Inmed Pharmaceuticals Inc. current report, 17 November 2022

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Inmed Pharmaceuticals Inc. on November 17, 2022. The company is incorporated in British Columbia and its common shares trade on The Nasdaq Stock Market LLC under the symbol INM. The filing primarily addresses changes in senior financial leadership.

Key Financial Metrics

This filing is a current report regarding corporate governance and personnel changes. It does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent 10-K or 10-Q filings for financial performance details.

Material Changes

  • Departure of Interim CFO: The Company terminated the consulting agreement with Brenda Edwards, effective November 20, 2022. Ms. Edwards had served as Interim Chief Financial Officer since April 1, 2022.
  • Internal Promotion: Sarah Li, the Company's Controller since January 2020, has been promoted to Vice President of Accounting and Controller and Principal Accounting Officer.
  • Search for Leadership: The Company is currently in discussions to finalize the engagement of interim financial leadership (CFO) consulting services.

Outlook, Risks, and Management Commentary

Management has issued a press release (Exhibit 99.1) confirming the termination of Ms. Edwards' agreement. The filing notes that the company is actively seeking to replace the interim CFO role. No specific financial risks, contingencies, or unusual items were disclosed in this specific report beyond the operational impact of the leadership transition.

Key Facts for Investor Verification

  • Verify the timeline for the appointment of a new Interim CFO to ensure continuity in financial reporting.
  • Confirm the effective date of Brenda Edwards' departure (November 20, 2022) against internal records.
  • Review the press release (Exhibit 99.1) for any additional context regarding the transition not included in the 8-K text.
  • Check subsequent filings for the appointment of the new financial leadership.